Meeting
2014 Genitourinary Cancers Symposium
Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).
Authors
Zafar Malik
Clatterbridge Cancer Centre, Bebington, United Kingdom
Zafar Malik , Giuseppe di Lorenzo , Sergio Bracarda , Alexandros Ardavanis , Mert Basaran , Phillip Parente , Wito de Schultz , Fred Saad , Inge van Oort , Winald R. Gerritsen , Luis M. Antón Aparicio , Geoffrey Matus , Simon Hitier , Axel Heidenreich , Amit Bahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01254279
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 242)
DOI
10.1200/jco.2014.32.4_suppl.242
Abstract #
242
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.
First Author: Zafar Malik
Poster
2015 Genitourinary Cancers Symposium
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)
First Author: Ethan M. Basch
Poster
2013 ASCO Annual Meeting
PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger
Poster
2013 Genitourinary Cancers Symposium
Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).
First Author: Sergio Bracarda